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Introduction
Asthma is known to humanity since ancient times. 
The name asthma is derived from ancient Greek meaning 
gasping or panting. The description of asthma dates back 
to Hippocrates (460 - 357 BC) who first described asthma 
spasms, and to Galen (201-130 BC) who defined asthma 
symptoms and established that asthma was caused by bron-
chial obstructions. Despite long history, it was believed that 
asthma is a disease of adults; only with industrialization was 
acknowledged that asthma also affects children.
Childhood asthma: how big the problem really is?
Based on the largest cross-sectional study from ISAAC 
Phase Three study, which included 193,404 children aged 
6-7 years from 66 centers in 37 countries, and 304,679 chil-
dren aged 13-14 years from 106 centers in 56 countries, 
asthma has a prevalence of 10% to 30% in children world-
wide (1). With such magnitude, asthma is the forerunner 
chronic medical condition in childhood worldwide. In US 
alone, the prevalence of asthma among children more than 
doubled in less than 2 decades (1980-1996) and has reached 
an alarming 9.4% in 2008 (2), up from 8.9% in 2005 (2).
Morbidity and mortality from childhood asthma:  es-
timated and hard-to-estimate costs
Health care use for asthma in all ages includes outpa-
tient visits to doctors’ offices and hospital outpatient depart-
ments, visits to hospital emergency departments (EDs), and 
hospitalizations (1-3); the pediatric population adds the 
financial burden from the missed school days, estimated 
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Abstract
Background:  The article reviews aims to promote the communication between scientists engaged in basic research and clinicians working with children, 
in order to better understand the mechanism and work together towards an optimal management of this prominent pediatric condition. We reviewed the 
recent advancements in regards to pediatric asthma related to pathogenesis, diagnostic criteria and differential diagnosis, and peer-reviewed evidence for 
efficiency of pharmacological and non- pharmacological/alternative/adjuvant treatment; we also emphasize the importance of education of all parties 
involved in care, outpatient management, age-appropriate involvement of children in their own care, and asthma prevention measures in children. Clinically 
asthma is characterized by recurrent episodes of wheezing, dyspnea, and cough; at the pathophysiological level the airway wall thickness is increased and 
involves both smooth muscle and collagen tissue, the mucous glands and mucus production are increased, and the vascularity of the airways is increased, 
all leading to chronic inflammatory remodeling of the airways and resulting in reduction of lung function. 
Conclusions:  Asthma among children has been on the rise for decades. With an estimated prevalence of 10-30%, asthma is the most prevalent chronic 
disease of pediatric population worldwide and one with a large health care burden. The approach to diagnosis and treatment of asthma in children is 
distinct from adults; so is the management, prevention and the education of parties involved in care. Recently there has been a significant progress in 
mechanistic understanding of asthma; further, asthma management in children is becoming a top priority.
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12.8 million in children 5-17 old, and from days that their 
parents miss from work while taking care of their children 
(3). In 2005 in US, children had 7.0 million visits and an 
outpatient visit rate of 958 per 10,000 pediatric population. 
Children also had over 754,000 ED visits, at a rate of 103 
per 10,000. The ED visit rate was highest among children 
aged 0-4 years at 168 per 10,000. Among children 0-17 
years, there were 198,000 hospitalizations (27 per 10,000). 
Hospitalizations were highest among children 0-4 years, 60 
hospitalizations per 10,000. Among children, asthma deaths 
are rare (2.3). In contrast, asthma causes significant morbid-
ity and is the most frequent reason for preventable child-
hood hospitalizations (4). In addition to the sizable costs, 
there are largely underestimated costs from the psychologi-
cal burden of asthma on children due to impaired quality of 
life, long-term health outcomes of childhood asthma during 
adulthood, and impaired quality of life in caregivers (5).
The face of childhood asthma: age, gender, race, genetic 
background, socio-economic status, access to and quality of 
child care and more
Age. Asthma often appears in early childhood, is diag-
nosed by 3.5 years of age in most of children who will devel-
op childhood asthma and the rate keeps at steady frequency 
by 5.5 years (1-3). While it is difficult to predict the pro-
spective identification of asthma phenotype and its clinical 
course, it is currently estimated that 3 out of 4 school-aged 
children with asthma will have outgrown their disease by 
mid-adulthood. The risk of persistence of childhood asthma 
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into adulthood increases with severity, sensitization, expo-
sure to environmental offending agents including smoke, 
and female gender (7).
Gender. As of 2005, in US asthma prevalence for boys 
(10%) was 30% higher than for girls (7.8%) (3); it has been 
reported that hormonal status is important for asthma de-
velopment, however it remains to be determined which fac-
tors contribute to the fact that more adult women are diag-
nosed with asthma than adult men (8).
Race and population/ethnicity. According to Akinbami 
LJ et al, at least in US, there are no significant differences 
in asthma prevalence between race groups (9). In contrast, 
asthma-related morbidity is higher among black children. 
Among racial categories, black children are most likely to 
have activity limitations due to asthma but only if they are 
economically disadvantaged: 49% of those who were also 
and poor were limited compared with about 20% of black 
non-poor, white poor, and white non-poor children (9). 
Even when access to healthcare is accounted for, as de-
scribed in a study by Stewart KA et al involving children 
whose parents were in the military and who therefore had 
access to health insurance and treatment, black children 
were more likely to be diagnosed with asthma than either 
Hispanic or white children (9.6% versus 8.0% and 6.3%, 
respectively) (10). Black children with an asthma diagno-
sis also were more likely than Hispanic or white children 
to have a potentially avoidable hospitalization for asthma 
(2.6% versus 2.0% and 1.3%, respectively) or for any other 
medical reason (2.9% versus 2.2% and 1.6%, respectively) 
(10). Finally, black poor children had the lowest level of 
ambulatory care use for asthma after accounting for disease 
severity (9). Besides being linked to race, asthma prevalence 
in the US varies drastically between diverse US popula-
tions/ethnicities (11). In US, asthma prevalence is highest 
in minorities, including Puerto Ricans, African Americans, 
Filipinos, Irish Americans, and Native Hawaiians, and low-
est in Mexicans and Koreans (12-14). Mortality rates from 
asthma-related morbidity follow similar trends in all races 
and ethnicities; response to medication, including Salbuta-
mol, is lower in descendants of Indian and Puerto Rican ori-
gin than in African Americans or Mexicans (15,16). Asthma 
prevalence also differs between populations of the same eth-
nicity who are born and live in different places (17). US-
born Mexican populations, for example, have higher asthma 
rates than non-US born Mexican populations that are living 
in the US (18).
Genetic background. There are compiling data suggest-
ing that the genetic background may be implicated in sus-
ceptibility, and severity, of asthma. Studies from Thomsen 
SF et al showed that the risk of asthma in the co-twin of an 
affected twin was higher in mono-zygotic than in di-zygot-
ic twins (19). The risk of asthma in the co-twin decreased 
with increasing age at onset of asthma in the index twin; the 
effect was attenuated in di-zygotic twins relative to mono-
zygotic twins. According to these studies, genetic factors 
explain ~34% of the variation in the age at onset of asthma, 
and environmental factors account for ~66% (19).
Current literature indicates that asthma signs and symp-
toms are more common in those with alpha-1 antitrypsin 
deficiency (AATD) (20), or mutations in DENND1B, a pro-
tein that interacts with the tumor necrosis factor (TNF) α 
receptor and represses inflammatory-cell TNF-receptor 
signaling (21), ADAM33 (ADAM metallopeptidase domain 
33, a disintegrin and metalloproteinase domain 33) (22) or 
in sphingosine-1-phosphate receptor (S1PR1), a regulator of 
vascular permeability and an essential participant regulating 
lung vascular integrity and responses to lung inflammation 
(23). Children with CHIT1 mutations are at higher risk for 
severe asthma with fungal sensitization (24). The genome-
wide association studies (GWASs) revealed an asthma-pre-
disposing SNP signature in interleukin 1 receptor- like 1/
interleukin 18 receptor 1 (IL1RL1/IL18R1), dipeptidyl-pep-
tidase 10 (DPP10), phosphodiesterase 4D (PDE4D), V-myb 
myeloblastosis viral oncogene homolog (MYB), PDE10A, 
IL33, and especially protein tyrosine phosphatase, receptor 
type D (PTPRD) genes. In addition, rs10938397 near glu-
cosamine-6- phosphate deaminase 2 (GNPDA2) and pro-
tein kinase C alpha (PRKCA) were top gene SNPs common 
among both increased BMI (obesity) and asthma (25). In 
contrast, TLR2/rs7656411 TT variant homozygote had a 
significantly reduced risk of asthma when compared with 
those with the GG wild- type homozygote. Furthermore, 
a positive association was observed between the T allele of 
rs2381289 in TLR6 and allergic rhinitis in asthma, while 
the A allele of rs11466651 in TLR was negatively associated 
with allergic rhinitis (26). MHC haplotype has significant 
effect on CD8 cell response and is an important determi-
nant of the outcome of neonatal RSV infection; it remains 
to be determined if these factors are important for virus-
dependent sensitization and development of asthma (27). 
Collectively these data suggest a role for innate immunity 
and inflammation in asthma.
Socio-economic status. The incidence of asthma is highest 
among low-income populations; such disparity is observed 
in US and worldwide (9, 28). Asthma deaths are most com-
mon in countries with low income and in neighborhoods 
with limited income and increased frequency of ethnic mi-
norities. Given the fact that asthma has been strongly as-
sociated with the presence of household insects, including 
cockroaches; and the most prevalent presence of these in-
sects in low-income neighborhoods, it is also indicative of 
association between low socio-economic status and asthma. 
It remains to be determined if limited resources and/or lim-
ited access to medical care can account for the low incidence 
of and treatment quality for asthma that varies significantly 
among different racial groups (29). For example, poor Af-
rican Americans are less likely to receive outpatient treat-
ment for asthma, more likely to require an emergency room 
visit or hospitalization for their asthma symptoms and have 
higher likelihood as a race of dying from an asthma attack 
compared to whites. The prevalence of “severe persistent” 
asthma is also greater in low-income communities than 
those with higher income (29, 30).
Access to and quality of child care. A study by Gurka et al 
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shows that the number of children in the child-care environ-
ment when the child was a toddler is significantly associated 
with odds of asthma, even after adjusting for respiratory ill-
nesses and other risk factors (31). The fewer the children 
are exposed to triggering agents as toddlers, the higher the 
probability of persistent or late-onset asthma by age 15 (31).
Epigenetic. It is well established that maternal, and even 
paternal, health status, and their habits, such as consump-
tion of alcohol or tobacco, may influence the health of the 
off-spring; such connections were closely established for low 
birth weight infants, immunity, and obesity. More recently, 
Folic acid taken in supplement form in late pregnancy was 
associated with an increased risk of childhood asthma at 3.5 
years and with persistent asthma (32).
Pathophysiology of asthma
Asthma is characterized by inflammation and hyper-
reactivity of airway in response to triggering agents that 
include allergens such as pollen or mold, viral respiratory 
infections, or other stimuli/irritants, such as tobacco smoke, 
cold and exercise. How the irritants trigger asthma is less 
well understood; in case of allergens and viruses, they are 
inhaled and taken up by the epithelial and immune cells in 
the upper airways and in the lungs. Upon exposure to trig-
gers, a complex immune cascade is initiated in both innate 
and adaptive immune cells (33-37). Innate immune cells, 
including macrophages and dendritic cells, are activated 
and attempt to eliminate the trigger by degradation while 
producing pro-inflammatory signals, including cytokines 
and chemokines. In addition, innate immune cells process 
the triggering molecules and present them to adaptive im-
mune cells, including T and B lymphocytes (34). Lympho-
cytes attack the infected/damaged cells in the airways, by 
cytokines/chemokines, and by secreted antibodies. It is be-
lieved that Th2 is predominant in asthma with production 
of IL-4, IL-5, IL-9, and IL-13. IgE production by B cells is 
most detrimental in asthma. Altogether, these complex im-
mune reactions promote inflammation, which further ac-
tivate the release of pro-inflammatory mediators from and 
recruitment of mast cells, macrophages, eosinophils and 
other immune cells in the airways (35). It is this complex 
response that collectively causes injury of the airway epi-
thelium, prolonged contraction of smooth muscle, edema 
and glandular hypertrophy followed by exaggerated secre-
tion of mucus; inflamed airways become more narrow and 
obstructed and are further hyper-responsive to subsequent 
stimuli (35,36). Airway obstruction can develop suddenly 
or gradually and accounts for asthma symptoms. In the long 
run, if the inflammation and hyper-responsiveness persist, 
a remodeling of the airway occurs. Airway thickening of all 
components of the airway wall (inner, outer, and total) oc-
curs in long-term asthma from the epithelial hypertrophy, 
mucus metaplasia, increased muscle mass from myofibro-
blast hyperplasia, and connective tissue deposition followed 
by sub-epithelial fibrosis (33). All these events contribute 
to progressive decline in lung function and continuous 
sensitivity to trigge-ring agents in asthma (33-37) (fig. 1). 
However, it is wise to acknowledge that our understanding 
of the mechanisms of asthma is yet minimal, even with the 
fast pace of recent discoveries in the areas of environmental 
biology, immunology, omics (genomics, proteomics, inter-
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actomics) and our symbiosis with airway, skin and gut mi-
crobiota. While we managed to identify individual players 
in many of the processes involved in asthma, we still lag be-
hind in our ability to connect all the discoveries in a bigger 
picture of asthma. In these conditions, extensive research is 
needed, more than ever, to fully understand the pathogen-
esis of asthma, with special focus on early pediatric age.
Clinical manifestations of asthma in childhood
Clinically asthma is characterized by recurrent episodes 
of wheezing, shortness of breath, cough and chest tightness. 
Symptoms are often worse at night or in the early morning, 
and often occur in response to exercise, cold air or trigge-
ring allergens.
The diagnostic process of asthma
Accurate diagnosis is critical in pediatric asthma; unfor-
tunately in pediatric population additional difficulties are 
often encountered in the diagnosis process, including the 
intermittent and non-specific clinical presentation, limited 
ability of the patient caregiver to present a detailed history 
of the disease in the proband and health status in related 
family, etc. Nevertheless, several clues are available to aid 
the diagnosis of asthma in children. First, asking the right 
questions in a case when asthma is suspected helps: history 
of cough occurring with or without colds which are aggra-
vated at night, recurrent wheezing, dyspnea and chest tight-
ness, some or all of which are precipitated or aggravated by 
physical activity, exposure to house dust, smoke, animals 
with fur, nature (grass, pollens) or alternating emotions are 
suggestive of asthma. Second, collection of disease history 
from the proband can be employed in children as early ages 
of ~5 years old; it is important to note what their individual 
perception of symptoms is and how they define the effects 
of their disease on their quality of life. Third, family history 
is of great importance: asthma, eczema, eosinophilia, aller-
gies, smoking may suggest of origins of asthma. Fourth, a 
focused physical exam of a child is warranted when asthma 
is suspected: include respiratory tract, chest, and skin, but 
do not overlook the general health (nourishment status, 
neurological and musculo-skeletal status, intellectual status, 
age-specific milestones).
Diagnostic criteria of asthma in childhood
Currently there is no precise diagnostic test for asthma. 
Similar to good old days, when medicine was solely based on 
the ability of the physician to recognize a disease by a com-
bination of clinical symptoms, asthma is largely a symptom-
based diagnosis today.  The Expert Panel from Asthma Edu-
cation and Prevention Program (NAEPP) of the National 
Heart, Lung, and Blood National Institute has issued the G3 
report in 2007 outlining the Guidelines for the Diagnosis 
and Management of Asthma (38). In this report the experts 
recommended that essential elements in asthma evaluation 
include the history, symptoms, physical examination, and 
assessment of quality of life, as well as therapeutical trial 
with medications are key in the diagnosis of asthma in 0–4 
years of age group, while 5–11 years of age group is to be 
analyzed as adults, based on detailed medical history, physi-
cal exam focusing on the upper respiratory tract, chest, and 
skin (including identification of episodic symptoms of air-
flow obstruction or airway hyperresponsiveness, airflow ob-
struction), and exclusion of alternative diagnoses. Spirom-
etry to demonstrate obstruction and assess reversibility was 
recommended in children 5 years of age or older; reversibil-
ity was determined in these guidelines either by an increase 
in FEV1 of ≥12 percent from baseline or by an increase ≥10 
percent of predicted FEV1 after inhalation of a short-acting 
bronchodilator. It is thus clear that the NAEPP recommen-
dations, listed in table 1, do not fully distinguish between 
adults and children older than 5 years of age. NAEPP speci-
fies that spirometry is needed to establish a diagnosis of 
asthma; further, spirometry is recommended at the time of 
initial diagnosis, after treatment is initiated and symptoms 
are stabilized, whenever control of symptoms deteriorates, 
and every 1 or 2 years on a regular basis.
Table 1
The NAEPP recommendations  
for diagnostic criteria of asthma
•  Wheezing-high-pitched whistling sounds when breathing out. 
Lack of wheezing and a normal chest examination do not exclude 
asthma.
•  History of any of the following:
o Cough, worse particularly at night
o Recurrent wheeze
o Recurrent difficulty in breathing
o Recurrent chest tightness
•  Symptoms occur or worsen in the presence of:
o Exercise
o Viral infection
o Animals with fur or hair
o House-dust mites (in mattresses, pillows, upholstered furniture, 
carpets)
o Mold
o Smoke (tobacco, wood)
o Pollen
o Changes in weather
o Strong emotional expression (laughing or crying hard)
o Airborne chemicals or dusts
o Menstrual cycles
•  Symptoms occur or worsen at night, awakening the patient
Table 2
Diagnostic criteria of asthma used  
by the British Thoracic Society
BTS recommendations are based on the ‘response to therapy’ ap-
proach: a positive response to treatment, assessed as reversibility of 
airway obstruction, is considered diagnostic of asthma.
BTS recommends that airflow measurement is diagnostic when:
• ≥20% difference on at least three days in a week for at least two weeks;
• ≥20% improvement of peak flow following treatment, for example:
o 10 minutes of inhaled β-agonist (e.g., salbutamol);
o six weeks of inhaled corticosteroid (e.g., beclometasone);
o 14 days of 30 mg prednisolone.
• ≥20% decrease in peak flow following exposure to a trigger (e.g., 
exercise).
REvIEw ARTIClES The Moldovan Medical Journal, June 2018, Vol. 61, No 2
The British Thoracic Society (BTS) recommends the 
‘response to therapy’ approach for asthma diagnosis (39). 
A positive response to treatment, assessed as reversibility 
of airway obstruction, is considered diagnostic of asthma. 
Further, BTS recommends airflow measurement with a 
peak flow meter or spirometer. The BTS diagnostic criteria 
for asthma are listed in table 2; similar to NAEPP recom-
mendations (tab. 4), the BTS recommendations do not fully 
distinguish between adults and children.
Spirometry
Spirometry is necessary to confirm the diagnosis of 
asthma, but can be also useful in assessing the degree of 
congestion. Two conditions are to be assessed: baseline and 
post-inhalation of a short- acting beta agonist (SABA); two 
parameters are to be measured during spirometry, including 
forced vital capacity (FVC) and forced expiratory volume in 
1 second (FEV1), and the FEV1/FVC ratio is to be calcu-
lated. Due to the great need for cooperation from the patient 
during spirometry, this procedure is recommended only for 
children older than 5 years old. Disproportionate limitation 
of FEV1 compared to FVC, indicated by decreased FEV1/
FVC ratio, is diagnostic of obstructive disease; the response 
to SABA is indicative of the reversibility of airway obstruc-
tion. If the post-SABA FEV1 rises with more than 200ml 
or +12% compared to the baseline, the airway obstruction 
is considered reversible. If the spirometry results are not 
conclusive and the diagnosis of asthma is still suspected, a 
bronchial provocation with histamine or methacholine may 
be employed. This test is limited to those with >65% pre-
served FEV1; a -20% FEV1 post-stimulation is indicative of 
asthma.
Differential diagnosis of asthma
There are several diseases that are often misdiagnosed as 
asthma; among the first criteria to use for a differential diag-
nosis of asthma in childhood is the child’s age. In infants the 
differential diagnosis task is relatively easy, because asthma 
is seen relatively rarely in this age group and it is often con-
sidered as a differential rather than the primary diagnosis. 
In older children, differential diagnosis of asthma often re-
quires thorough investigation. Nevertheless, excellent di-
agnostic skills are required from the physician in order to 
accurately diagnose asthma at all ages.
In an infant:
1. Transient infant wheezing occurs early in life; however, 
it is without clear ties to atopy but with clear relationship to 
maternal smoking.
2. Milk aspiration, due to neurological problems or ana-
tomical defects, is usually associated with feeding, and if left 
untreated, is associated with lung infections and develop-
mental delays.
3. Structural abnormalities of the bronchial tree (tracheo-, 
broncho-malacia) are often manifested shortly after birth 
and only pose difficulty in differentiation when are mani-
fested later in life.
4. Cardiac failure associated with congenital or acquired 
heart diseases is rarely a problem for asthma differentiation 
at any age.
5. Inhalation of foreign body can occur in any age and 
is often presented with an acute onset and shows differen-
tial air entry in addition to wheezing; when not removed 
promptly it may be mistaken with asthma and needs a de-
tailed history, thorough examination and imaging.
6. Vascular rings/laryngeal webs. Vascular rings (VR) are 
caused by the abnormal persistence of embryonic tissue that 
comprises the aortic arch because of double aortic arch (50-
60%), right aortic arch with an aberrant left subclavian (12-
25%), or pulmonary artery sling. VRs often present with a 
clinical picture of tracheo-esophageal compression, wheez-
ing and stridor or sudden apneic and cyanotic spells; they are 
often diagnosed as recurrent bronchiolitis. Laryngeal webs 
are caused by failure of normal embryonic tissue regression; 
depending on the severity of anatomical defect, the LW often 
present with varying degress of respiratory distress ranging 
from severe subglottic stenosis diagnosed at birth with respi-
ratory failure to identification in older children with weak 
cry, horseness and recurrent croup. Instrumental investiga-
tion is useful for the differential diagnosis in these cases: la-
ryngoscopy and lateral neck films are useful for LW, while 
barium swallow and MRI are often used for VR.
In older children, the differential diagnosis of asthma re-
quires a more extensive investigation as candidate diseases 
are more abundant.
1. Genetic disorders, such as cystic fibrosis (CF) and pri-
mary ciliary dyskinesia (PCD) should be always on the 
watch. CF may be suspected if the recurrent wheezing is 
associated with failure to thrive. PCD may be suspected 
in infancy, when supplemental oxygen is needed early 
postnatally, or later in life when present with wheezing 
and cough; however it stands apart from asthma due to 
its association with recurrent otitis, sinusitis and situs 
inversus.
2. Viral infections accompanied with bronchiolitis may re-
sult in a lingering wheezing and dyspnea.
3. Eosinophilic lung disorders (ELD), including allergic 
bronchopulmonary aspergilosis, can be often mistaken 
with asthma, however, in ELD the serum IgE is often 
elevated, along with positive imaging picture (chest in-
filtrates) and positive skin prick test to Aspergillus an-
tigen.
4. Mental health problems, such as anxiety-associated 
hyperventilation, depression and panic disorders, are 
often seen on older children and the triggering factor 
is clearly not of allergic nature; little or no wheezing is 
present and the spirometry parameters lack FEV abnor-
mality.
5. Vocal cords dysfunction (VCD) is rare in children how-
ever, it may present with episodic, abruptly starting and 
stopping wheezing, cough and severe difficulty brea- 
thing; unlike asthma, where inspiratory flow is ob-
structed, the VCD is associated with a preserved expi-
ratory loop and flow and flattened expiration.
6. Churg-Strauss vasculitis (CSV) may be mistaken with 
asthma, especially at the early disease stages. However, 
unlike asthma, CSV is accompanied by anemia, persistent 
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eosinophilia, raised erythrocyte sedimentation rate and 
positive anti-neutrophil cytoplasmic antibody in 30-
50% of patients; the definitive diagnosis of CSV requires 
biopsy of the lungs and other affected organs.
7. Enlarged lymph nodes or tumors (head and neck, me-
diastinal) can press the respiratory pathways to mimic 
asthma; targeted evaluation of these conditions should 
be performed in children when both inspiratory and 
expiratory flows are affected, even if no symptoms of 
infection/inflammation or cancer are observed.
8. Exertional dyspnea (ED) may be the most challenging to 
distinguish from asthma, however in ED symptoms are 
present exclusively during exercise. A particular chal-
lenge in children is the differential diagnosis of exertion 
asthma (EA).
9. Pulmonary embolism (PE) is seen in ever younger adults 
and may occur in teens. While difficulty breathing in PE 
may be mistaken with asthma, a thoroughly collected 
anamnesis, a rapidly progressing clinical course with 
acute onset of symptoms and rapid deterioration of re-
spiratory function, aided by indicative imaging investi-
gations are key for differential diagnosis.
Several co-morbidities and triggering factors that are 
often difficult to separate from asthma; these are usually 
present in older children.
1. Diseases of upper airways, such as chronic rhinosinusitis 
and nasal polyps, are frequently associated with severe 
asthma. Nasal congestion/obstruction, purulent nasal 
and/or retropharyngeal discharge, facial pain or pres-
sure, hypo- or an-osmia, ear pressure/fullness and hali-
tosis despite adequate dental hygiene, are suggestive, 
while nasal endoscopy and imaging of the nasal cavity 
and sinuses are confirmative of rhinosinusitis and na-
sal polyps (40). Medical or surgical treatment of upper 
airways diseases have been proven useful in mana- 
ging asthma in adults. Conversely, patients with severe 
asthma should be systematically evaluated for upper 
airways diseases.
2. Gastrointestinal reflux (GERD) is common in patients 
with asthma however rarely causes severe asthma 
symptoms. Regurgitation, dysphagia, heartburn, ody-
nophagia, excessive salivation, nausea, chest/upper ab-
dominal pain, chronic cough, laryngitis, and erosion 
of dental enamel are suggestive of GERD. Although a 
24hrs pH monitoring is needed to confirm the GERD, 
most physicians prefer an empiric therapy trial with 
proton pump inhibitors.
3. Obesity is a co-morbidity factor for childhood asthma. 
According to Sulit et al, childhood obesity raised the 
risk for asthma by 1.8 times and the risk of wheeze 1.6 
times (41). It is yet to be identified if the association 
between asthma and obesity is causal. It is interesting, 
however, that calorie restriction improves clinical find-
ings and reduces airway inflammation in overweight 
adults with moderate asthma and has long-term health 
benefits, including improvement of asthma symptoms 
(42,43); such events are expected but yet to be defined 
in pediatric population.
Management of childhood asthma: severity assess-
ment
The assessment of severity is among the most difficult 
tasks in managing pediatric asthma. The criteria for distin-
guishing the severity stages in acute and interval asthma are 
listed in tables 3 and 4, respectively. The golden rule while 
assessing the severity of asthma in children is to observe of-
ten and act promptly; ultimately preventing progression of 
severity is highly-desired an achievement.
Management of childhood asthma: pharmacological 
treatment
Asthma is both an easy and a difficult disease: in the for-
mer scenario the response to therapy is fast and complete; 
Table 3
Severity assessment criteria for acute asthma episodes
Manifestation/Symptom Severity
Severe-to-life
threatening
Moderate Mild
Observational
/Subjective
Ability to talk Unable to speak or
separate words
Phrases Sentences
Consciousness Agitated, confused/drowsy or 
Absent
Normal Normal
Central cyanosis Present Possible Absent
Wheezing Quiet Moderate to loud Variable
Objective Oxymetry (SaO2) <90% 90-95% Above 95%
Pulse rate >200/min 100-200/min <100/min
FEV1 Unable to perform spirometry or 
<40% predicted value
40-60%
predicted value or previous 
baseline value
>60% predicted value or 
previous baseline value
PEF Unable to perform or <40% predic-
ted value
40-60%
predicted value or previous 
baseline value
>60% predicted value or 
previous baseline value
REvIEw ARTIClES The Moldovan Medical Journal, June 2018, Vol. 61, No 2
however, when the response to therapy is poor, asthma be-
comes a difficult disease to treat and even more difficult one 
to manage long-term. Management of asthma depends on 
the severity and the disease stage at which the medical pro-
fessional encounters the child.
In acute asthma, the assessment of severity (tab. 3) will 
precede and largely determine the treatment; these children 
should be assessed promptly and in a calm/comfortable at-
mosphere, in order to prevent agitation and thus worsening 
of the respiratory insufficiency. The pharmacological treat-
ment, described in detail in table 5, is aimed at reversing/
managing the bronchial constriction and airway inflam-
mation and limiting mucus production. The children with 
acute asthma should be accommodated in the best-possible 
psychologically-comforting and temperature-regulated en-
vironment and should be monitored often. Inhaled oxygen, 
b2-agonists, and anticolinergics, and systemic (per os) cor-
ticosteroids are used in mild and moderate asthma attacks, 
their doses are dependent on age/body weight. More severe 
asthma attacks require more energetic measures towards 
decreasing the airflow resistance and enhancing airway 
penetration achieved with heliox and i/v bronchdialators, 
including salbutamol, aminophilline and magnesium sul-
phate, and aided by leukotriene receptor antagonists. The 
therapy is considered efficient when the patients oxygen-
ation is maintained >95%, the symptoms subside and the 
respiratory parameters are restored. Alternative and adju-
vant therapies and psychotherapy are rarely considered dur-
ing the management of acute episode of asthma in a child.
In interval asthma, the management is aimed to main-
tenance of good control/ remission (defined as lack of 
symptoms, lack of limitations to activities and sleep, early 
morning symptoms, exercise induced cough or wheeze, low 
frequency of bronchodilator use, preservation of lung func-
tions) and prevention/limitation of recurrences/exacerba-
tions (by desensitization to allergens, prevention of inflam-
mation/remodeling, limitation of therapies and their side 
effects). The frequency of acute episodes and any chronic 
symptoms should be reviewed often and action should be 
initiated promptly. In terms of pharmacotherapy, the first 
choice should be given to inhaled corticosteroids; spacer de-
vices should be used at all ages, even in younger children in 
whom use of low volume spacer device with a well-sealing 
face mask may be needed. In addition, allergen immuno-
therapy, alternative anti- inflammatory agents (macrolides, 
xantines, ketotifen) should be considered, when indicated. 
A key component of interval asthma management is the 
non-pharmacological intervention, including diet, man-
aged physical activity, and healthy life style. Preventive 
treatment should be initiated if there are frequent acute epi-
sodes or chronic symptoms (more than one disturbed night 
per week, difficulty participating in physical activities, or 
bronchodilator use on more than one day per week).
In a nut-shell, the approach to asthma therapy in child-
hood is on step-by-step nature, as detailed in figure 2. The 
therapy is administered on sliding scale basis depending on 
the severity of symptoms, should be tapered as soon as the 
symptoms subside, and should aim to a symptom-free pe-
riod during which asthma is considered as well controlled. 
As with many chronic diseases, in which cures are not yet 
available, a sustained remission is the target of asthma man-
agement.
Management of childhood asthma: management plan
Children with asthma usually see a healthcare provider 
every one to six months to monitor the child’s symptom se-
verity and frequency and response to treatment. If asthma 
control has been adequate for at least three months, the 
asthma medication dose may be decreased. If control is 
not adequate, the medication schedule, delivery technique, 
and trigger avoidance will be reviewed, and the medication 
Table 4
Severity assessment criteria for interval asthma
Severity Intermittent Persistent
Infrequent Frequent Mild Moderate Severe
Day-time symptoms 
between exacerbations
None None >1/week but not every 
day
Daily Continual
Night-time symptoms 
between exacerbations
None None <2/month and not 
every week
>1/week frequent
Exacerbation Brief, mild, occurs 
every 
4-6 weeks
>2/month <2/week
Affects activity and/
or sleep
>2/week
Restricts activity 
and/or affects sleep
Frequent
Restricts activity 
and/or affects sleep
FEV1 or PEF >80%
predicted value 
or previous base-
line value
At least 80% 
predicted value 
or previous base-
line value
At least 80% 
predicted value or 
previous baseline 
value
60-80%
predicted value 
or previous 
baseline value
<60%
predicted value 
or previous 
baseline value
PEF variability <20% <20% 20-30% <30% <30%
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dose may need to be increased. Asthma management goals 
in children are: symptom free with near normal PFTs; sleep 
and exercise without asthma symptoms, prevent exacerba-
tions, and minimize medication side effects; none of these is 
possible without an adequate compliance with the manage-
ment plan.
National Asthma Education and Prevention Program 
Guidelines recommend a multimodal, chronic care ap-
proach to asthma (38). In this context, the most important 
component of the management of children with asthma is 
a specific, customized plan aimed to proactively monitor, 
identify symptoms in a timely fashion and manage symp-
toms that involves the caregiver, the child, if sufficiently old, 
and the medical professional. The treatment plan should be 
discussed, understood, and agreed upon by all involved par-
ties; the plan should be written down, available at all time 
for review and adjusted according to changes in symptoms 
in a timely fashion (48). The healthcare provider may also 
recommend keeping a daily asthma diary when symptoms 
are not well controlled or when starting a new treatment; a 
periodic diary may be recommended for children who have 
stable symptoms and whose medications have not changed 
recently.
Management of childhood asthma: challenges for all 
involved parties
There are challenges for all the involved parties as it re-
lates to following the management plan of a child with asth-
ma; these are related to the age and individual characteris-
tics of the child with asthma, availability and quality of the 
caregiver, access to medical care, environmental conditions.
The caregiver has to be someone who understands the 
importance of reducing the child’s exposure to allergens, 
capable of pro-active monitoring the early appearance of 
the symptoms, and diligent with administering/supervis-
ing the therapy of asthma in an outpatient setting. The 
most often encountered challenges for caregivers are poor 
socioeconomic status and restricted financial means, lead-
ing to inability to protect the children from exposure to al-
lergens, and thus dealing with a never- ending vicious circle 
of disease progression. In acute asthma exacerbations, the 
ability of the caregiver to recognize the symptoms and their 
ability to make arrangements for the delivery of the child to 
medical care facility in a timely fashion is critical. In interval 
asthma management, the most challenging task of the care-
giver is to prolong an exacerbation-free period along with a 
healthy life style with age- appropriate activities. The most 
challenging of all tasks for caregivers is to cope with the spe-
cific life style that an asthmatic child brings into the family, 
all in an efficient yet gracious, cheerful and loving manner.
The children should be encouraged to participate in their 
own care, as soon as they are sufficiently old to understand 
the goals and the management plan. Younger children need 
Fig. 2. Management of childhood asthma.
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to be protected from the symptom-triggering environmen-
tal exposure and educated to keep calm upon exacerbations, 
as stress exacerbates asthma attacks (49). Older children can 
monitor and identify their symptoms in a timely fashion and 
even responsibly manage their symptoms with prescribed 
pharmacological agents. Older children are often tempted 
by outdoor activities where they can be exposed to cold, 
athletics with strenuous physical activity, interactions with 
their peers in crowded, enclosed and thus germ-spreading 
environments, all of which precipitate asthma symptoms; 
thus, they need close coaching of their daily lives in order to 
successfully manage their asthma.
The Medical Professionals are often challenged with dif-
ficult differential diagnosis of asthma, especially at extreme 
childhood ages, rapid progression of the severity of asthma 
exacerbations, poor management of the diseases requiring 
ever in need for adjustment pharmacological therapy and 
insufficient time for outpatient management/follow-up. It is 
important to stress the need for a follow- up in this particu-
lar disease at any stage of care: scheduling an appointment 
after an emergency department visit increases the likeli-
hood that urban children with asthma would follow up with 
a PCP (50). Fifield J. et al reported in a recent paper that 
redesigned medical support is the key to asthma manage-
ment in children (51). By providing quarterly well-asthma 
visits using structured visit forms, community health work-
ers for outreach and follow-up, a Web-based disease regis-
try for tracking and scheduling, and a provider education 
package, the medical professionals have a great potential to 
truly follow the multimodal, chronic care approach recom-
mended by the National Asthma Education and Prevention 
Program Guidelines (38,51). Indeed, when intervention 
sites were given an additional Web- based, computerized 
patient-specific provider feedback system that produced a 
guideline-driven medication assessment prompt, the asth-
ma control improved significantly for each of the following 
visits, suggesting that practice redesign can improve pro-
vider adherence to treatment guidelines as well as patients’ 
asthma control (51).
Management of physical exercise in childhood asthma
The physical activity is not to be avoided in children with 
asthma; moreover, it is to be encouraged, and aim to be of 
age-appropriate strenuous and symptom-free. In prevent-
ing asthma exacerbation upon physical exercise, it is recom-
mended to consult a medical professional before start for 
comprehensive assessment and thorough planning, start 
any regimen slowly, keep continuity or warm up gradually 
at the beginning of each session, avoid cold weather, protect 
the airway by warming the inspired air. In those who can-
not fully comply with these recommendations due to their 
geographical location or nature of exercise, administer 1-2 
puffs of quick and short acting beta agonist (SABA) 5 min-
utes before starting to exercise.
Management of childhood asthma: adjuvant and al-
ternative treatment
Adjuvant therapy aims to provide support to asthma 
management in addition to the basic therapeutic regimen. 
A relatively new approach to long-term care for patients 
with asthma is the blocking of IgE with monoclonal anti-
bodies (52). Detailed studies of efficiency of such approach 
in pediatric populations are underway; however, this is not 
a first-line therapy that will only work in severely atopic pa-
tients. In the newer vision of asthma therapy, the inhaled 
steroids are now recommended in children older than 5 
years with persistent asthma; leukotriene modifiers have 
shown only marginal benefit and are not recommended as 
first-line therapy or add-on therapy (53).
Alternative medicine (AM) (“holistic”, “unconventional”, 
“complementary”) includes a broad range of treatments 
and practices that have not gained wide acceptance in the 
traditional medical community and so are not considered 
standard medical treatment. While used in as many is ¼ 
of adults with asthma (54) and suggested to be useful for 
asthma control, the alternative medicine use in children is 
limited. A study by Torres-Llenza et al revealed that alter-
native medicine use among Quebec children with asthma 
remained modest (13%), with vitamins, homeopathy and 
acupuncture being the most popular modalities (55). AM 
use was associated with preschool age, was highly correlat-
ed with ethnicity and episodic asthma. More importantly, 
AM was also associated with poor asthma control (55). The 
efficiency of AM in childhood asthma remains to be identi-
fied.
Differences between pediatric and adult asthma
For the general practitioners who do not deal with pedi-
atric asthma on daily basis, it is important to summarize the 
differences between the pediatric and adult asthma. More 
recently Bush and Menzies- Gow (56) pointed to the age-
related variation of asthma phenotypes and classified these 
age-specific differences based on:
a) Phenotypes of wheezing: often encountered during 
the first year of life, many remit in the second year of life, 
and the children who remit do not have later-onset wheeze.
b) Gender/atopy bias: children with severe asthma have 
no gender bias and are highly atopic, in contrast to the fe-
male-preponderant, non-atopic bias seen in adults.
c) Lung function: unlike adults, children with severe 
asthma have relatively well-preserved lung function.
In terms of pharmacological treatment strategy, children 
younger than 5 years of age are more difficult to diagnose, 
treat and manage and require specific approaches; children 
older than 5 years of age are treated similar to adults, with 
planned management according to diseases severity and 
with medication doses corresponding to body weight.
Recent discoveries in asthma research field that pro-
mise translational advancement
While avoidance of allergens is often recommended as a 
primary prevention measure, this is often not possible, not 
feasible or not effective especially in children. Thus, new 
preventive measures are needed; in this context measures 
that aim at naturally occurring mechanisms that might nor-
mally limit the development of immune reactions, inflam-
mation and tissue remodeling are most desirable.
Most recently there are several research discoveries that 
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look promising in terms of taking advantage of the innate 
immune responses as means to manage asthma. To date, 
most researchers in asthma field agree with the “hygiene 
hypothesis” of asthma and attempt to employ innate im-
munity- mediated approaches to modulation of adaptive 
immunity as means to manage asthma. Innate immunity 
(macrophages, dendritic cells) recognizes pathogen-de-
rived molecules by sensing specific patterns in their struc-
ture via Pattern Recognition Receptors (PRR) (34-37). The 
microbe-specific molecules that are recognized by a given 
PRR are called pathogen-associated molecular patterns 
(PAMPs), they alert the innate immune cells to bacterial 
carbohydrates (e.g. lipopolysaccharide or LPS, mannose), 
nucleic acids (e.g. bacterial or viral DNA or RNA), bacerial 
peptides (flagellin), peptidoglycans and lipotechoic acids 
(from Gram positive bacteria), N-formylmethionine, lipo-
proteins and fungal glucans. PRRs that sense endogenous 
stress signals are called danger-associated molecular pat-
terns (DAMPs); they sense substances released by stressed 
or dying cells, including uric acid, heat shock proteins etc. 
Table 5
Pharmacotherapy of acute asthma episode
Action Time-line Mild episode Moderate episode Severe Life-threatening episo-de (critical)
Hospitalization Immediately Usually not
needed
May be
needed
Usually needed; may 
need intensive care
Needed, intensive care
Observation Immediately Continuous during the
1st hour, assess after 20 
min post- treatment
Continuous during the 
1st hour, assess after 60 
min post- treatment
Continuous, assess 
often as needed
Continuous, assess often 
as needed
Oxygen Immediately As needed, monitor 
SaO2
As needed, monitor 
SaO2
Required, monitor
SaO2
Required, monitor
SaO2
Heliox (helium/
oxygen mixture)
Immediately No No May be considered
SABA (short- acting 
B2 agonist)
Salbutamol (100ug/
puff )
Immediately Age
<6yo
Age
>6yo
Age
<6yo
Age
>6yo
Age
<6yo
Age
>6yo
All ages
4-6
puffs
8-12
puffs
6
puffs
12
puffs
6 puffs,
3 times 
during the 
1st hour
12
puffs, 3 ti-
mes during 
the 1st hour
Nebulizer
Review in 20 
minutes
Give every 1-4 hrs, as 
needed
If inadequate response: 
-repeat 2 more times at 
20 min intervals -give 
every 1-4 hrs thereafter
If no effect , bolus IV sal-
butamol (15um/kg) over 
10 minutes, then 1ug/kg/
min thereafter
If no effect in 20 min, 
bolus IV salbutamol 
(15um/kg) over 10 
minutes, then 1ug/
kg/min thereafter
Ipratropim (20ug/
puff)
Immediately Not necessary Optional Age
<6yo
Age
>6yo
All ages
2 puffs 4 puffs Nebulizer
Every 20 minutes, 3 doses 
during the 1st hour or use 
in nebulizer
Continuous
Corticosteroids Immediately Usually not neces-
sarily.
Consider depend-
ing on the clinical 
dynamics
Oral prednisone (1mg/
kg) daily for up to 3 
days
Oral prednisone (1mg/kg) 
daily for up to 5 days.
Consider IV
methylprednisone.
Methylprednisone 
IV (1mg/kg) every 
6 hours on 1st day, 
every 12 hrs on 2nd 
day, and daily there-
after.
Magnesium During the first 
hour
No No Magnesium sulfate 50% 0.1 ml/kg
(50mg/kg) over 20 min, than 0.06 ml/kg (0.06mg/
kg) to achieve target serum 1.5-2.5 mM/L
Aminophylline Usually after the 
first hour assess-
ment
No No Only in intensive care:
loading dose 10 mg/kg; maintenance dose: 
1.1 mg/kg/hr if
<9yo, and 0.7 mg/kg/hrs if >9yo.
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All these receptors trigger production of pro-inflammatory 
cytokines and initiate, maintain, and participate in resolu-
tion of inflammation. At experimental level, it is possible 
to employ innate immune tolerance (57-59) or adaptive 
immune responses (60-63) to control asthma mechanisms; 
it remains to be determined if these findings have transla-
tional value. Even with the promising progress of research, 
the question remains: can manipulation of immune system 
aid asthma management?
Unequivocally yes, because inflammation is key to 
pathogenesis of asthma; however, it is to be noted that ma-
nipulation of immune system, along with identification of 
genetic conditions, and modulation of environmental fac-
tors will be needed in order to provide personalized therapy 
of asthma to children.
Future directions
Several research directions are emergent, in the light of 
ever-growing number of asthma- affected children:
1. Detailed understanding of the processes of sensiti-
zation, inflammation, airway reactivity and remodeling 
is emerging in order to arrive to a sound prevention and 
much needed pathogenesis-based treatment asthma. In this 
context, we foresee that the need for research of allergens, 
developmental immunology, airway microbiota and omics 
(genomics, proteomics, interactomics). While this type of 
research is expected to yield data useful for asthma in gen-
eral, age-specific characteristics and immune response in 
the airways are yet to be fully understood.
2. Discoveries of new pharmacotherapy for asthma are 
also awaited: we are in need of new targets with high speci-
ficity, low toxicity, convenient delivery and limited side-ef-
fects.
3. A better understanding of the immediate and long-
term effects of existing combination asthma therapies, along 
with development of more efficient assessment, treatment 
and follow-up protocols, are among the clinical priorities.
4. We need better social support for the asthmatic chil-
dren and their families in terms of safe housing conditions 
preventing/minimizing exposure to allergens, access to 
consistent and quality medical care, availability and ad-
equate conditions for physical activity. Finally, education of 
all parties involved in care for asthmatic children requires 
expansion: we need dedicated and excellently-trained medi-
cal personnel at all levels, access for caregivers to relevant 
literature about the latest discoveries in areas of asthma re-
search, diseases prevention and management, and last, but 
not least, we need a step-by-step action plan on how to edu-
cate affected children to efficiently deal with asthma on daily 
bases and yet have a productive and enjoyable life.
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